Global Emphysema Drug Market By Type (Paraceptal, Pentrilobular and Panlobular), Mechanism of Action Type (Bronchodilators, Beta-agonists, Anticholinergics, Corticosteroids, Phosphodiesterase -4 Inhibitors and Mucolytics), Stages Type (Very Mild or Stage 1: FEV1 is About 80.0% of Normal, Moderate or Stage 2: FEV1 is Between 50.0% and 80.0% of Normal, Severe or Stage 3: FEV1 is Between 30.0% and 50.0% of Normal and Very Severe or Stage 4: FEV1 is Lower Than in Stage 3, or The Same as Stage 3 But With Low Blood Oxygen Levels), Therapy Type (Oxygen Therapy and Protein Therapy), Drug Type (Aclidinium, Formoterol, Salmeterol, Levalbuterol, Ipratropium, Olodaterol, Ffluticasone, Budesonide and Prednisolone), Route of Administration (Oral, Inhaled, Intravenous and Others), Surgery Type (Lung Volume Reduction Surgery and Lung Transplant Surgery), Device Type (Inhalers, Pressurized Metered-Dose Inhalers (MDIS) , Dry-Powder Inhalers (DPIS), Nebulizers and Soft Mist Inhalers), End Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
Global Emphysema Drug Market Analysis and Size
Global emphysema drug market has experienced significant growth due to the influenced by factors like demographic changes, smoking prevalence, technological advancements, and regulatory developments.
Data Bridge Market Research analyses that the global emphysema drug market which was USD 4,474.54 million in 2022, is expected to reach USD 8,174.54 million by 2030, and is expected to undergo a CAGR of 6.30% during the forecast period 2023-2030. This indicates that the market value. “Paraceptal” dominates the type segment of the global emphysema drug market owing to prevalence of emphysema. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Emphysema Drug Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Paraceptal, Pentrilobular and Panlobular), Mechanism of Action Type (Bronchodilators, Beta-agonists, Anticholinergics, Corticosteroids, Phosphodiesterase -4 Inhibitors and Mucolytics), Stages Type (Very Mild or Stage 1: FEV1 is About 80.0% of Normal, Moderate or Stage 2: FEV1 is Between 50.0% and 80.0% of Normal, Severe or Stage 3: FEV1 is Between 30.0% and 50.0% of Normal and Very Severe or Stage 4: FEV1 is Lower Than in Stage 3, or The Same as Stage 3 But With Low Blood Oxygen Levels), Therapy Type (Oxygen Therapy and Protein Therapy), Drug Type (Aclidinium, Formoterol, Salmeterol, Levalbuterol, Ipratropium, Olodaterol, Ffluticasone, Budesonide and Prednisolone), Route of Administration (Oral, Inhaled, Intravenous and Others), Surgery Type (Lung Volume Reduction Surgery and Lung Transplant Surgery), Device Type (Inhalers, Pressurized Metered-Dose Inhalers (MDIS) , Dry-Powder Inhalers (DPIS), Nebulizers and Soft Mist Inhalers), End Users (Hospitals, Homecare, Specialty Clinics and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GlaxoSmithKline plc. (UK), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Eli Lilly And Company.(U.S.), Astrazeneca (UK), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited.(Japan), Bristol-Myers Squibb Company (U.S.), Sanofi (France), Bayer AG (Germany), AbbVie Inc. (U.S.), Allergan (Ireland), Precigen.(U.S.), Pulmonx Corporation (U.S.), Halozyme, Inc.(U.S.), Mariposa Health (U.S.), Kamada Pharmaceuticals. (Israel) Olympus Corporation (Japan), Spiration, Inc.(U.S.) and Lifetech Scientific (China)
|
|
Market Opportunities
|
|
Market Definition
Emphysema drug encompasses all pharmaceutical products and therapies designed to diagnose, treat, or manage emphysema, a debilitating respiratory condition primarily caused by smoking, environmental factors, or genetic predisposition. These products include bronchodilators, anti-inflammatory drugs, oxygen therapy, and novel biopharmaceuticals.
Global Emphysema Drug Market Dynamics
Drivers
- Growing Aging Population
The aging population is a significant driver for the global emphysema drug market. Emphysema is more prevalent among older individuals due to cumulative exposure to risk factors like smoking and environmental pollutants. As the world's population continues to age, the demand for emphysema drugs and therapies is expected to rise. This demographic trend is particularly evident in developed countries where life expectancy is increasing. Additionally, the elderly population often experiences comorbidities, and emphysema exacerbates these conditions. As a result, healthcare providers and payers are increasingly focusing on managing emphysema to improve the overall health and quality of life of older patients.
- Rising Smoking Rates in Emerging Markets
Smoking remains a leading cause of emphysema, and emerging markets have witnessed a surge in smoking rates. This trend is primarily driven by factors such as urbanization, increased disposable income, and aggressive marketing by tobacco companies in these regions.
- Advancements in Drug Delivery Systems
The pharmaceutical industry has made significant strides in developing advanced drug delivery systems tailored to emphysema treatment. Inhalers, nebulizers, and other inhalation devices have improved the effectiveness and convenience of delivering medications to the lungs. These advancements enhance patient compliance as they make it easier for individuals to self-administer medications. Moreover, they allow for the precise delivery of drugs to the affected areas of the lungs, minimizing side effects and maximizing therapeutic benefits.
Opportunities
- Biopharmaceutical Advancements
The development of biopharmaceuticals, including monoclonal antibodies and gene therapies, holds promise for the emphysema drug market. These advanced therapies can provide more targeted and effective treatments, potentially slowing disease progression and improving patient outcomes. Biopharmaceuticals also offer opportunities for personalized medicine, tailoring treatment plans to individual patient profiles, which can enhance therapeutic efficacy and reduce side effects.
- Telemedicine and Remote Monitoring
The rise of telemedicine and remote monitoring technologies has transformed the way healthcare is delivered. These technologies enable healthcare providers to remotely monitor emphysema patients, assess their condition, and adjust treatment plans as needed. Telemedicine improves access to care, especially for patients in rural or underserved areas. It also enhances patient education and medication adherence, ultimately leading to better disease management and outcomes
Restraints/Challenges
- High Treatment Costs
One of the significant challenges in the emphysema drug market is the high cost associated with treatments and therapies. Medications, inhalers, oxygen therapy, and other interventions can be expensive, placing a financial burden on patients, especially those without adequate health insurance coverage. This cost barrier can limit access to essential treatments and lead to non-compliance, negatively impacting patients' health and quality of life. It also creates disparities in healthcare, as only those with financial resources can afford the best available care.
- Side Effects and Adverse Reactions
Many emphysema drugs have potential side effects and adverse reactions, including cardiovascular complications and other health risks. These side effects can limit the use of specific medications in certain patient populations, particularly those with underlying health issues.
This global emphysema drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global emphysema drug market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In March 2022, The department of veteran’s affairs launched its novel HER in Columbus, Ohio at the VA Central Ohio healthcare system
Global Emphysema Drug Market Scope
The global emphysema drug market is segmented on the basis of type, mechanism of action type, stages type, therapy type, drug type, route of administration, surgery type, device type and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Paraceptal
- Pentrilobular
- Panlobular
Mechanisms of Action Type
- Bronchodilators
- Beta-Agonists
- Anticholinergics
- Corticosteroids
- Phosphodiesterase-4 Inhibitors
- Mucolytics
Stage Type
- Very Mild or Stage 1: FEV1 Is About 80.0% of Normal
- Moderate or Stage 2: FEV1 Is Between 50.0% and 80.0% of Normal
- Severe or Stage 3: FEV1 Is Between 30.0% and 50.0% of Normal and Very Severe or Stage 4: FEV1 Is Lower Than in Stage 3
- The Same as Stage 3 But with Low Blood Oxygen Levels
Therapy Type
- Oxygen Therapy
- Protein Therapy
Drug Type
- Aclidinium
- Formoterol
- Salmeterol
- Levalbuterol
- Ipratropium
- Olodaterol
- Fluticasone
- Budesonide
- Prednisolone
Route of Administration
- Oral
- Inhaled
- Intravenous
- Others
Surgery Type
- Lung Volume Reduction Surgery
- Lung Transplant Surgery
Device Type
- Inhalers
- Pressurized Metered-Dose Inhalers (MDIS)
- Dry-Powder Inhalers (DPIS)
- Nebulizers
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Global Emphysema Drug Market Regional Analysis/Insights
The global emphysema drug market is analysed and market size insights and trends are provided by country, type, mechanism of action type, stages type, therapy type, drug type, route of administration, surgery type, device type and end users as referenced above.
The countries covered in the emphysema drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global emphysema drug market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period 2023-2030. This is because of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.
Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period 2023-2030 owing to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The emphysema drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for emphysema drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the emphysema drug market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Emphysema Drug Market Share Analysis
The global emphysema drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global emphysema drug market.
Some of the major players operating in the global emphysema drug market are:
- GlaxoSmithKline plc.(UK)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Eli Lilly and Company. (U.S.)
- Astrazeneca (UK)
- Pfizer Inc.(U.S.)
- Takeda Pharmaceutical Company Limited. (Japan)
- Bristol-Myers Squibb Company (U.S.)
- Sanofi (France)
- Bayer AG (Germany)
- AbbVie Inc.(U.S.)
- Allergan (Ireland)
- Precigen (U.S.)
- Pulmonx Corporation (U.S.)
- Halozyme, Inc.(U.S.)
- Mmariposa Health (U.S.)
- Kamada Pharmaceuticals (Israel)
- Olympus Corporation (Japan)
- Spiration, Inc.(U.S.)
- Lifetech Scientific (China)
SKU-